- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
January 25th, 2005
Lumera Corp. announced it has acquired the exclusive rights to Helix Biopharma's Heterodimer Protein Technology (HPT). The technology moves Lumera closer to launching a unique product set aimed to capitalize on the multi-billion dollar proteomic array market.
The combination of the Helix HPT technology and Lumera's proprietary nanosurface modification chemistry will, for the first time, allow researchers to consistently take existing DNA arrays to produce protein arrays that accurately mimic the native living cell environment of the body.
|Related News Press|
Leti Announces Launch of First European Nanomedicine Characterisation Laboratory: Project Combines Expertise of 9 Partners in 8 Countries to Foster Nanomedicine Innovation and Facilitate Regulatory Approval July 1st, 2015
Clues to inner atomic life from subtle light-emission shifts: Hyperfine structure of light absorption by short-lived cadmium atom isotopes reveals characteristics of the nucleus that matter for high precision detection methods July 3rd, 2015